Patent ID: 11957661
Assignee: INCYTE CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method for treating non-segmental vitiligo in a subject, said method comprising administering to the subject a therapeutically effective amount of JAK1 pathway inhibitor 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a pharmaceutically acceptable salt thereof, wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof is administered in a daily dose of about 10 mg to about 80 mg on a free base basis.